Status:
COMPLETED
Orlistat Treatment of Crigler-Najjar Disease
Lead Sponsor:
University Medical Center Groningen
Collaborating Sponsors:
Erasmus Medical Center
De Najjar Stichting
Conditions:
Crigler-Najjar Syndrome
Eligibility:
All Genders
8+ years
Phase:
NA
Brief Summary
The purpose of this study was to determine whether orlistat is effective in decreasing plasma unconjugated bilirubin levels in patients with Crigler-Najjar disease.
Detailed Description
Unconjugated hyperbilirubinemia in Crigler-Najjar (CN) disease is conventionally treated with phototherapy and/or phenobarbital. Life-long daily phototherapy has considerable disadvantages. Main probl...
Eligibility Criteria
Inclusion
- patients with Crigler-Najjar disease above the age of 7 years
Exclusion
- cholestasis, chronic malabsorption syndrome, pregnancy
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
End Date :
January 1 2004
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00461799
Start Date
September 1 2003
End Date
January 1 2004
Last Update
April 18 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Erasmus University Medical Center
Rotterdam, Netherlands, 3015 GJ